Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3)

Diagnostic Cytopathology

Volumn 37, Issue 12, 2009, Pages 865-870

  Nassar, Aziza ^a   Cohen, Cynthia ^b   Siddiqui, Momin ^b  

^a MAYO CLINIC   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell blocks; Rabbit monoclonal antibodies; SP1; SP2; SP3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SP1; MONOCLONAL ANTIBODY SP2; MONOCLONAL ANTIBODY SP3; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CONTROLLED STUDY; FALSE POSITIVE RESULT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RABBITS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 72149084361     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21121     Document Type: Article

References (19)

1. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 2002;117:723-728.
2. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. (Pubitemid 350003059)
3. Cheang MC, Treaba DO, Speers CH, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 2006;24:5637-5644.
4. Huang Z, Zhu W, Szekeres G, Xia H. Development of new rabbit monoclonal antibody to estrogen receptor: Immunohistochemical assessment on formalin-fixed, paraffin-embedded tissue sections. Appl Immunohistochem Mol Morphol 2005;13:91-95. (Pubitemid 40283809)
5. Huang Z, Zhu W, Meng Y, Xia H. Development of new rabbit monoclonal antibody to progesterone receptor (Clone SP2): No heat pretreatment but effective for paraffin section immunohistochemistry. Appl Immunohistochem Mol Morphol 2006;14:229-233.
6. Powell WC, Hicks DG, Prescott N, et al. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: Comparison with CB11. Fluorescence in Situ Hybridization (FISH) and Interlaboratory Reproducibility. Appl Immunohistochem Mol Morphol 2007;15:94-102.
7. Carlson RW, Moench SJ, Hammond EH, et al. HER2 Testing in breast cancer: NCCN task force report and recommendations. J Natl Compr Canc Netw 2006;4 (S3):S1-S22.
8. Ricardo S, Milanezi F, Carvalho S, Leitao D, Schmitt F. HER2 evaluation through the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol 2007;60:1001-1005. (Pubitemid 47441932)
9. Gown AM, Yaziji H. Accuracy and precision in HER2/neu testing in breast cancer: Are we there yet? Hum Pathol 2004;35:143-146.
10. Briffod M, Hacene K, Le Doussal V. Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases. Mod Pathol 2000;13:841-850. (Pubitemid 30643830)
11. Cano G, Milanezi F, Leitao D, Ricardo S, Brito MJ, Schmitt FC. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2. Diagn Cytopathol 2003; 29:207-211. (Pubitemid 37193648)
12. Wludarski SC, Bacchi CE. High concordance of SP3 rabbit monoclonal antibody with FISH to evaluate HER2 in breast carcinoma. Appl Immunohistochem Mol Morphol 2008;16:466-470.
13. Wang S, Saboorian HM, Frenkel EP, et al. Aneusomy 17 in breast cancer: Its role in Her-2/neu protein expression and implication for clinical assessment of Her-2/neu status. Mod Pathol 2002; 15: 137-145. (Pubitemid 34171323)
14. Cianciulli AM, Botti C, Coletta AM, et al. Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of Her-2 in breast cancer. Cancer Genet Cytogenet 2002;133: 66-71. (Pubitemid 34224878)
15. Thomson TA, Hayes MM, Spinelli JJ, et al. Her-2/neu in breast cancer: Interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 2001;14:1079-1086.
16. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004;291: 1972-1977. (Pubitemid 38544278)
17. Lebeau A, Deimling D, Kaltz C, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19:354-363. (Pubitemid 32112846)
18. Hoang MP, Sahin AA, Ordonez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000;113:852-859. (Pubitemid 33051521)
19. Rossi S, Laurino L, Furlanetto A, et al. Rabbit monoclonal antibodies: A comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol 2005;124:295-302. (Pubitemid 41060143)